Lexicon Pharmaceuticals (NASDAQ:LXRX) Earns Buy Rating from HC Wainwright

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report)'s stock had its "buy" rating reaffirmed by HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $4.00 price objective on the biopharmaceutical company's stock.

Separately, Needham & Company LLC reaffirmed a "hold" rating on shares of Lexicon Pharmaceuticals in a report on Wednesday, January 29th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $2.50.

Lexicon Pharmaceuticals Stock Performance

Shares of Lexicon Pharmaceuticals stock traded up $0.03 during trading on Monday, hitting $0.37. 12,941,614 shares of the company's stock traded hands, compared to its average volume of 3,985,907. Lexicon Pharmaceuticals has a 1 year low of $0.28 and a 1 year high of $2.83. The business has a 50-day simple moving average of $0.74 and a 200-day simple moving average of $1.16. The stock has a market capitalization of $90.54 million, a P/E ratio of -0.49 and a beta of 1.04. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 7.43.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last announced its quarterly earnings results on Thursday, March 6th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.02. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. As a group, analysts forecast that Lexicon Pharmaceuticals will post -0.66 EPS for the current year.

Remove Ads

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Several large investors have recently made changes to their positions in the company. BNP Paribas Financial Markets grew its holdings in Lexicon Pharmaceuticals by 71.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 31,853 shares of the biopharmaceutical company's stock valued at $50,000 after buying an additional 13,246 shares in the last quarter. Bayesian Capital Management LP bought a new position in shares of Lexicon Pharmaceuticals during the 4th quarter valued at approximately $31,000. RPO LLC purchased a new position in shares of Lexicon Pharmaceuticals in the fourth quarter valued at $33,000. Renaissance Technologies LLC bought a new stake in Lexicon Pharmaceuticals in the fourth quarter worth $38,000. Finally, Arizona State Retirement System raised its stake in Lexicon Pharmaceuticals by 34.4% during the fourth quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company's stock valued at $47,000 after purchasing an additional 16,136 shares in the last quarter. 74.70% of the stock is owned by institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.